Explore the Demand for Antibody-mediated Rejection Prevention in USA — analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036

Future Market Insights

Demand for Antibody-mediated Rejection Prevention in USA

Key Insight

The demand for antibody-mediated rejection prevention in USA is projected to grow from USD 43.3 million in 2026 to USD 178.9 million by 2036, at a CAGR of 15.2%. Monoclonal Antibodies will dominate with a 42.0% market share, while hospitals will lead the end user segment with a 68.0% share.

January 05, 2026

Anurag Sharma

250 Pages

Cite this Report

Demand for Antibody-mediated Rejection Prevention in USA

https://www.futuremarketinsights.com/reports/united-states-antibody-mediated-rejection-prevention-market

License

Buy Now

Summary ToC Companies

Key Players

Alexion (AstraZeneca)
Bristol-Myers Squibb
Genentech (Roche Holding AG)
Novartis
Sanofi Genzyme

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Demand for Antibody-mediated Rejection Prevention in USA

Key Players

Similar Industry Reports